Shlomi Raz, Eleusis CEO
Psychedelics biotech set to go public via SPAC — pushing IV form of psilocybin into PhI
Psychedelics biotech Eleusis has its eyes on an expansion, and it’s going the SPAC route to get it.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
